Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis

Brain

Volumn 126, Issue 10, 2003, Pages 2304-2311

  Evoli, Amelia ^a   Tonali, Pietro A ^a   Padua, Luca ^a   Lo Monaco, Mauro ^a   Scuderi, Flavia ^a   Batocchi, Anna P ^a   Marino, Mariapaola ^a   Bartoccioni, Emanuela ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

MuSK; Myasthenia gravis; Plasma exchange; Seronegative myasthenia gravis; SF EMG

Indexed keywords

AZATHIOPRINE; CHOLINESTERASE INHIBITOR; CYCLOSPORIN A; EDROPHONIUM; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; MUSCLE SPECIFIC KINASE ANTIBODY; NEOSTIGMINE; PREDNISONE; PROTEIN ANTIBODY; PYRIDOSTIGMINE; UNCLASSIFIED DRUG; AUTOANTIBODY; CHOLINERGIC RECEPTOR; CYCLOSPORIN; MUSK PROTEIN, HUMAN; PROTEIN TYROSINE KINASE;

ADOLESCENT; ADULT; AGED; ARTICLE; ASSISTED VENTILATION; BULBAR PARALYSIS; CHILD; CLINICAL FEATURE; CLINICAL OBSERVATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DIARRHEA; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG RESPONSE; ELECTROMYOGRAM; FACE MUSCLE; FEMALE; GENERAL CONDITION IMPROVEMENT; HEAD; HOSPITALIZATION; HUMAN; IMMUNOASSAY; IN VITRO STUDY; INCIDENCE; INJECTION; LEG MUSCLE; MAJOR CLINICAL STUDY; MALE; MUSCLE ATROPHY; MUSCLE CONTRACTION; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; NERVE STIMULATION; ONSET AGE; PHARYNX; PHENOTYPE; PLASMAPHERESIS; PREVALENCE; PRIORITY JOURNAL; REFRACTORY PERIOD; RESPIRATORY TRACT DISEASE; SERODIAGNOSIS; SIDE EFFECT; SYMPTOMATOLOGY; THYMECTOMY; THYMUS; THYMUS ATROPHY; TOPOGRAPHY; TREATMENT OUTCOME; BLOOD; CASE CONTROL STUDY; CASE REPORT; ELECTROMYOGRAPHY; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; SEX RATIO;

ADOLESCENT; ADULT; AGE OF ONSET; AGED; AUTOANTIBODIES; AZATHIOPRINE; CASE-CONTROL STUDIES; CHILD; CYCLOSPORINE; ELECTROMYOGRAPHY; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; PLASMA EXCHANGE; PREDNISONE; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, CHOLINERGIC; SEX DISTRIBUTION; THYMECTOMY; THYMUS GLAND;

EID: 0242336467     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/awg223     Document Type: Article

References (32)

1. Apel ED, Glass DJ, Moscoso LM, Yancopoulos GD, Sanes JR. Rapsyn is required for MuSK signaling and recruits synaptic components to a MuSK-containing scaffold. Neuron 1997; 18: 623-35.
2. Bartoccioni E. Scuderi F, Scoppetta C, Evoli A, Tonali P, Guidi L, et al. Myasthenia gravis, thymectomy, and antiacetylcholine receptor antibody. J Neurol 1980; 224: 9-15.
3. Bergoffen J, Zmijewski CM, Fischbeck KH. Familial autoimmune myasthenia gravis. Neurology 1994; 44: 551-4.
4. Birmanns B, Brenner T, Abramsky O, Steiner I. Seronegative myasthenia gravis: clinical features, response to therapy and synthesis of acetylcholine receptor antibodies in vitro. J Neurol Sci 1991; 102: 184-9.
5. Bufler J, Pitz R, Czep M, Wick M, Franke C. Purified IgG from seropositive and seronegative patients with myasthenia gravis reversibly blocks currents through nicotinic acetylcholine receptor channels. Ann Neurol 1998; 43: 458-64.
6. Burden SJ. Building the vertebrate neuromuscular synapse. [Review]. J Neurobiol 2002; 53: 501-11.
7. Burges J, Vincent A, Molenaar PC, Newsom-Davis J, Peers C, Wray D. Passive transfer of seronegative myasthenia gravis to mice. Muscle Nerve 1994; 17: 1393-400.
8. DeChiara TM, Bowen DC, Valenzuela DM, Simmons MV, Poueymirou WT, Thomas S, et al. The receptor tyrosine kinase MuSK is required for neuromuscular junction formation in vivo. Cell 1996; 85: 501-12.
9. Drachman DB, Jones RJ, Brodsky RA. Treatment of refractory myasthenia: 'Rebooting' with high-dose cyclophosphamide. Ann Neurol 2003; 53: 29-34.
10. Evoli A, Batocchi AP, Zelano G, Uncini A, Palmisani MT, Tonali P. Familial autoimmune myasthenia gravis: report of four families. J Neurol Neurosurg Psychiatry 1995; 58: 729-31.
11. Evoli A, Batocchi AP, Lo Monaco M, Servidei S, Padua L, Majolini L, et al. Clinical heterogeneity of seronegative myasthenia gravis. Neuromuscul Disord 1996; 6: 155-61.
12. Heckmann JM, Morrison KE, Emerik-Szajewska B, Strugalska H, Bergoffen B, Willcox N, et al. Human muscle acetylcholine receptor alpha-subunit gene (CHRNA1) association with autoimmune myasthenia gravis in black, mixed-ancestry and Caucasian subjects. J Autoimmun 1996; 9: 175-80.
13. Herbst R, Burden SJ. The juxtamembrane region of MuSK has a critical role in agrin mediated signaling. EMBO J 2000; 19: 67-77.
14. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001; 7: 365-8.
15. Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, et al. Myasthenia gravis: recommendations for clinical research standards. Task force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. [Review]. Neurology 2000; 55: 16-23.
16. Keesey J. A treatment algorithm for autoimmune myasthenia in adults. Ann NY Acad Sci 1998; 841: 753-68.
17. Lindstrom J. An assay for antibody to human acetylcholine receptor in serum from patients with myasthenia gravis. Clin Immunol Immunopathol 1977; 7: 36-43.
18. Liyanage Y, Hoch W, Beeson D, Vincent A. The agrin/muscle-specific kinase pathway: new targets for autoimmune and genetic disorders at the neuromuscular junction. [Review]. Muscle Nerve 2002; 25: 4-16.
19. Mossman S, Vincent A, Newsom-Davis J. Myasthenia gravis without acetylcholine receptor antibody: a distinct disease entity. Lancet 1986; 1: 116-9.
20. Oh SJ. Electrophysiological characteristics in seronegative myasthenia gravis. Ann NY Acad Sci 1993; 681: 584-7.
21. Oosterhuis HJGH Myasthenia gravis. In: Clinical neurology and neurosurgery monographs. Edimburgh: Churchill Livingstone; 1984. p. 21-50.
22. Plested CP, Tang T, Spreadbury I, Littleton ET, Kishore U, Vincent A. AChR phosphorylation and indirect inhibition of AChR function in seronegative myasthenia gravis. Neurology 2002; 59: 1682-8.
23. Sanders DB, El-Salem K, Massey JM, McConville J, Vincent A. Clinical aspects of MuSK antibody positive seronegative MG, Neurology. In press 2003.
24. Schuberth HJ, Kroell A, Leibold W. Biotinylation of cell surface MHC molecules: a complementary tool for the study of MHC class II polymorphism in cattle. J Immunol Methods 1996; 189: 89-98.
25. Scuderi F, Marino M, Colonna L, Mannella F, Evoli A, Provenzano C, et al. Anti-p110 autoantibodies identify a subtype of 'seronegative' myasthenia gravis with prominent oculobulbar involvement. Lab Invest 2002; 82: 1139-46.
26. Soliven BC, Lange DJ, Penn AS, Younger D, Jaretzki A 3rd, Lovelace RE, et al. Seronegative myasthenia gravis. Neurology 1988; 38: 514-7.
27. Valenzuela DM, Stitt TN, DiStefano PS, Rojas E, Mattsson K, Compton DL, et al. Receptor tyrosine kinase specific for the skeletal muscle lineage: expression in embryonic muscle, at the neuromuscular junction, and after injury. Neuron 1995; 15: 573-84.
28. Verma PK, Oger JJ. Seronegative generalized myasthenia gravis: low frequency of thymic pathology. Neurology 1992; 42: 586-9.
29. Vincent A, Li Z, Hart A, Barrett-Jolley R, Yamamoto T, Burges J, et al. Seronegative myasthenia gravis. Evidence for plasma factor(s) interfering with acetylcholine receptor function. Ann NY Acad Sci 1993; 681: 529-38.
30. Vincent A, Bowen J, Newsom-Davis J, McConville J. Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets. [Review]. Lancet Neurol 2003; 2: 99-106.
31. Wallace BG, Qu Z, Huganir RL. Agrin induces phosphorylation of the nicotinic acethylcholine receptor. Neuron 1991; 6: 869-78.
32. Zhou H, Glass DJ, Yancopoulos GD, Sanes JR. Distinct domains of MuSK mediate its abilities to induce and to associate with postsynaptic specializations. J Cell Biol 1999; 146: 1133-46.